Novo Nordisk and Hims go from competitors to partners: The deal signals Novo’s desire to capture patients transitioning off compounded GLP-1s. All eyes turn to Eli Lilly, which at last check said it’s not affiliating with Hims.
Congress wants to end the pharma industry’s advertising expense write-offs: This has been proposed before, but under the new Trump administration’s anti-drug advertising stance, the bill could gain more traction and inspire other new rules.
The compounded GLP-1 market suffers another setback as Novo wins court case: Ads on social media for compounded weight loss drugs are still prevalent. But they’ll soon be subject to stricter regulatory oversight now that Big Pharma’s brand-name GLP-1s are available again.
Healthcare providers ages 50-70 are the most avid digital enthusiasts: HCPs are leaning into digital channels, but adoption varies among age cohorts. We dig into which digital channels they prefer, and implications for pharma companies looking to engage with HCPs.
GLP-1 users improve their health habits: Patients on the meds exercise more and eat better. Health and wellness brands have an opportunity to build relationships with consumers who are seeking health-focused products and services.
Big Pharma earnings don’t feel the impact of Trump's current tariffs—yet: Several large pharmas kept yearly financial guidance in place during Q1 earnings calls, highlighting how they’re absorbing current tariff costs. However, major business disruptions will take effect once Trump’s threat of 25% or more pharma tariffs lands.
Younger generations seek out medical advice from social media and their peers: “Doing my own research” is a health trend that took off during the pandemic. Healthcare providers and marketers must point out the dangers of trusting online medical misinformation while being more accessible on digital channels.
Eli Lilly sues telehealth companies over compounded weight loss drugs: Lilly is leaving no stone unturned when it comes to building a legal case to prevent compounded tirzepatide from being prescribed and sold.
Trump considers reviving a proposal that cuts US drug prices to international levels: It could be another blow to the drug industry, on top of ongoing drug price cuts in Medicare and looming tariffs set to hit the sector.
Only 30% of healthcare and pharma AI pilots make it to production: AI companies must demonstrate tech prowess, address security concerns, and drive clinical or business outcomes to convert more pilots into full-scale implementation..
RFK Jr.’s MAHA vision receives support in Indiana: Gov. Mike Braun issued nine executive orders aligning with Kennedy’s chronic illness agenda. But cuts to Medicaid funding could prevent these initiatives from having their intended effect.
Lilly notches another win in oral GLP-1 drugs: Eli Lilly’s phase 3 success could put it in a commanding position in diabetes and weight loss if the easy-to-take—and cheaper to manufacture—drug is approved.
The walls are closing in on the largest pharmacy benefit managers: Vertically integrated healthcare conglomerates may soon have to separate their pharmacy operations from their PBM businesses.
Abbott estimates millions in tariff costs, but may blunt some effects with $500 million investment in new US manufacturing: Pharma manufacturers currently under reprieve should pay attention to medtech industry effects and strategy shifts.
Trump says his drug pricing executive order will lower medication costs for Americans: But that could depend on how the Inflation Reduction Act’s “pill penalty” is addressed. The pharma industry is watching closely.
Health insurers’ digital tools lack basic capabilities: Medicare Advantage insurers must improve the digital experience since members can switch plans each year.
Brand-name drug prices could see the biggest jumps under newly promised tariffs: The Trump administration’s renewed push for pharma tariffs would mean higher drug manufacturing costs across the board, but especially for brand-name medicines.
Rapidly growing healthcare providers are reinvesting in online marketing: Incumbents must embrace social and search marketing to ward off competition from telehealth and D2C providers.
Pfizer’s push into weight-loss drugs suffers another setback: Novo Nordisk and Eli Lilly are cornering the market as pharma companies struggle to develop an effective weight-loss drug pill.